Researchers at Baylor College of Medicine have discovered a natural mechanism that clears existing amyloid plaques in the ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is one of the leading causes of dementia worldwide, and ...

A new study shows that oral arginine, a naturally occurring amino acid, can significantly suppress amyloid-β aggregation in Alzheimer’s disease models.

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...

Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology ...

A team of researchers at the Federal University of ABC (UFABC) in Brazil has developed a new chemical compound with the ...

A new blood test for Alzheimer’s disease may feel like a breakthrough for anyone seeking to understand the cause of their ...

A method for detecting early signs of Alzheimer's disease using amyloid PET imaging works as well as the previously used cerebrospinal fluid sample method. This is the conclusion of a new Lund ...

The idea that sticky brain plaques cause Alzheimer’s disease began as an interesting hypothesis and eventually became drug industry dogma. Now, after a string of clinical trial failures, that ...

Alzheimer's disease (AD) is thought to affect ∼10% of people over the age of 65 and ∼50% of people over 85. It is not the only disease that involves the abnormal deposition of proteins into structures ...